Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

TransEnterix announces Senhance robotic system program at Imperial College London and Imperial College Healthcare NHS Trust

TransEnterix, a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has installed a Senhance robotic surgical system in partnership with Imperial College London and St. Mary’s Hospital of the Imperial College Healthcare NHS Trust.

“Imperial College London and the Imperial College Healthcare NHS Trust are among the leading centers for minimally invasive surgical innovation in the world,” said Todd M. Pope, President and CEO at TransEnterix.

“We are delighted that they have chosen to add the Senhance system to their MIS program in general and colorectal surgery.”

“We are pleased to be the first center in the UK to use this new robotic technology,” said Professor Lord Ara Darzi, The Paul Hamlyn Chair of Surgery at Imperial College London. “Our centre thrives on combining promising technology with our skilled consultant surgical team to advance the field of minimally invasive surgery and we look forward to developing this program together.”

The Senhance is the first surgical system that brings haptic force feedback, eye-sensing camera control, and responsible economics through reusable instrumentation to robotics.

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.

The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control.

The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform.

The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States.